GRI Bio Q2 EPS $(1.31), Inline

GRI Bio (NASDAQ: GRI) reported quarterly losses of $(1.31) per share which met the analyst consensus estimate. This is a 97.88 percent increase over losses of $(61.85) per share from the same period last year.